Our research platform empowers researchers, nonprofits, life sciences organizations, payers, and academic labs to accelerate mental health research, generate evidence, and unlock insights.
In collaboration with preeminent experts at several top academic medical centers, we are analyzing the largest racemic ketamine dataset in the world to assess long-term patient outcomes throughout naturalistic repeated ketamine treatment.
In collaboration with the Ketamine Taskforce for Access to Safe Care and Insurance Coverage, we are conducting a prospective study on how ketamine affects activities of daily living and other functional outcomes in CRPS patients.
We are conducting a study on an innovative intramuscular racemic ketamine protocol to elucidate its efficacy and safety for the treatment of TRD, particularly around the relationship between dosage and time to relapse.
We are helping the Psychopathology Lab of McWelling Todman conduct a quality assurance study on a private ketamine-assisted psychotherapy practice, examining a range of quantitative and qualitative outcomes.
We are helping Fluence conduct a prospective study on psychedelic integration therapy to elucidate client and therapist characteristics, client outcomes, and access to care.